Disitamab vedotin plus carboplatin and bevacizumab as first-line and maintenance treatment for HER2-expressing, HRD-negative high-risk ovarian cancer

Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study

This study tests whether adding disitamab vedotin to carboplatin and bevacizumab helps people with HER2-expressing, HRD-negative high-risk ovarian cancer as first-line and maintenance treatment.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 43 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Jiangsu Cancer Institute & Hospital (Academic / other)
• Drugs / interventions: bevacizumab, chemotherapy, disitamab
• Locations: 2 sites (Nanjing, Jiangsu and 1 other locations)
• Trial ID: NCT07311577 on ClinicalTrials.gov

What this trial studies

This is a prospective, multicenter, single-arm phase II study enrolling 43 patients with pathologically confirmed HER2-expressing, HRD-negative high-risk ovarian cancer (FIGO stage III–IV). Participants receive disitamab vedotin combined with carboplatin (AUC 5 every 21 days) and bevacizumab (7.5–15 mg/kg every 21 days) as first-line therapy. Patients who achieve a complete or partial response continue maintenance with disitamab vedotin (up to 6 months) plus bevacizumab (until progression or up to 22 cycles) per investigator decision. HER2 expression must be documented locally and will be centrally confirmed, and eligible patients require measurable disease and ECOG performance status 0–1.

Who should consider this trial

Good fit: Ideal candidates are adults 18–75 with FIGO stage III–IV, pathologically confirmed HRD-negative high-risk ovarian cancer who have HER2 expression (IHC 1+–3+), measurable disease, ECOG 0–1, and adequate organ function.

Not a fit: Patients without HER2 expression, with HRD-positive disease, poor performance status, or significant organ dysfunction are unlikely to be eligible or to benefit from this treatment.

Why it matters

Potential benefit: If successful, this regimen could increase response rates and prolong progression-free survival for patients with HER2-expressing, HRD-negative high-risk ovarian cancer.

How similar studies have performed: Early-phase studies of disitamab vedotin and other HER2-targeted antibody–drug conjugates have shown activity in HER2-expressing tumors, but using RC48 with platinum and bevacizumab as first-line therapy in HRD-negative high-risk ovarian cancer is largely novel.

Eligibility criteria

Inclusion Criteria:

* Voluntary participation with written informed consent.
* Age 18-75 years.
* Expected survival ≥ 12 weeks.
* Histologically/cytologically confirmed advanced ovarian carcinoma (FIGO Stage III-IV).
* HRD-negative status per local assessment.
* High-risk features: macroscopic residual disease after primary cytoreductive surgery for Stage III; prior neoadjuvant chemotherapy; or Stage IV disease.
* ≥ 1 RECIST v1.1 measurable lesion (long-axis ≥ 10 mm by spiral CT or ≥ 15 mm short-axis for lymph nodes).
* HER2 expression documented locally (IHC 1+, 2+, or 3+); archival or fresh tumor tissue (paraffin block or unstained slides) must be available for central confirmation.
* ECOG performance status 0-1.
* Adequate organ function within 14 days before enrolment (no transfusion/haematinics/G-CSF allowed):

Haematology

1. Hb ≥ 90 g/L
2. WBC ≥ 3 × 10⁹/L
3. ANC ≥ 1.5 × 10⁹/L
4. PLT ≥ 90 × 10⁹/L Biochemistry

a) TBIL ≤ 1.5 × ULN b) ALT/AST/ALP ≤ 3 × ULN (≤ 5 × ULN if liver metastases) c) Serum creatinine ≤ 1.5 × ULN or CrCl ≥ 60 mL/min (Cockcroft-Gault)

* Urinalysis: dipstick proteinuria \< 2+ or 24-h urine protein \< 1 g.
* Cardiac function: NYHA class \< III and LVEF ≥ 50 % by echocardiography. -
* Women must be surgically sterile, post-menopausal, or use an approved contraceptive method from screening until 6 months after the last dose; serum pregnancy test negative within 7 days of first dose and not breastfeeding.
* Able and willing to comply with all study and follow-up procedures.

Exclusion Criteria:

* Non-high-risk histologic sub-types of ovarian carcinoma.
* CNS metastases and/or carcinomatous meningitis. -
* Requirement for parenteral hydration/nutrition OR clinical/radiologic evidence of partial bowel obstruction or perforation.
* ≥ Grade-2 peripheral neuropathy. -
* Active bleeding or high bleeding-risk conditions (e.g., known coagulopathy, tumour encasing major vessels).
* Interval between cytoreductive surgery and first bevacizumab dose \< 28 days.
* Concurrent malignancy or history of another primary malignancy within 5 years (except adequately treated in-situ cervix cancer, basal- or squamous-cell skin cancer).
* Major surgery within 4 weeks before first study dose and not fully recovered.
* Symptomatic or medically-requiring large-volume pleural effusion or ascites. - Live-attenuated vaccine within 30 days before first dose or planned during study.
* Significant arterial/venous thrombo-embolic or cerebro-cardiovascular event within 12 months before screening (e.g., DVT, PE, cerebral infarction, intracranial haemorrhage, MI); asymptomatic calf-muscle DVT not needing intervention or lacunar infarct without sequelae are allowed.
* Uncontrolled systemic diseases judged by investigator: diabetes, liver cirrhosis Child-Pugh B/C, interstitial pneumonitis, severe COPD, etc.
* Clinically-relevant cardiovascular disorders:

  1. PR interval \> 0.24 s or 2nd/3rd-degree AV block.
  2. Uncontrolled hypertension (SBP \> 150 mmHg or DBP \> 90 mmHg).
  3. MI, unstable angina or significant arrhythmia \< 6 months before enrolment.
  4. NYHA class ≥ II congestive heart failure.
  5. Serious arrhythmia requiring anti-arrhythmic therapy.
  6. ≥ Stage-II peripheral vascular disease (except transient ischaemia \< 24 h without permanent deficit and no surgery).
  7. Cerebrovascular accident within 6 months.
* Severe infection within 4 weeks before first dose (IV antibiotics/antifungals/ antivirals required) or unexplained fever \> 38.5 °C during screening; major surgery within 3 weeks.
* Active autoimmune or immunodeficiency disorders (e.g., autoimmune hepatitis, interstitial pneumonia, uveitis, RA, IBD, hypophysitis, vasculitis, nephritis). Exceptions: stable hypothyroidism on replacement, type-1 diabetes well controlled with insulin.
* Autoimmune disease requiring systemic immunosuppressive/immunomodulatory therapy within 2 years before first dose (stable replacement therapy with thyroxine, insulin or physiological corticosteroids permitted).
* Active or poorly controlled infection, including:

  1. HIV positive (HIV-1/2 antibody).
  2. Active hepatitis B (HBsAg positive or HBV DNA \> 2 000 IU/mL with abnormal LFT).
  3. Active hepatitis C (HCV antibody positive or HCV RNA ≥ 10³ copies/mL with abnormal LFT).
  4. Active tuberculosis.
  5. Other uncontrolled infection \> CTCAE v5.0 grade 2.
* History of other malignancy within 5 years (except adequately treated in-situ cervical cancer or basal/squamous-cell skin cancer). -
* Concurrent participation in another interventional clinical trial or investigational agent/device within 4 weeks before first dose. -
* Known hypersensitivity or intolerance to study drugs or their excipients. -
* History of substance abuse that cannot be abstained from, or any psychiatric disorder that may interfere with compliance.

Any other condition that, in the investigator's opinion, could increase risk or preclude safe completion of the protocol.

Where this trial is running

Nanjing, Jiangsu and 1 other locations

• Jiangsu Cancer Hospital — Nanjing, Jiangsu, China (Not_yet_recruiting)
• Jiangsu Cancer Hospital — Nanjing, Jiangsu, China (Recruiting)

Conditions Ovarian Cancer Metastatic; Ovarian Cancer Metastatic Recurrent; RC48; HRD-Negative High-Risk Ovarian Cancer; HER2-expressing